Advertisement Boston Therapeutics signs agreement to market SugarDown in US - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Boston Therapeutics signs agreement to market SugarDown in US

Boston Therapeutics has signed a consulting agreement with Generosus Advisors and Fortified Management Group to market SugarDown in the United States on a non-exclusive basis.

The marketing effort will be conducted via the Help Now Network (HNN), a healthcare marketing company and its affiliates.

SugarDown is a dietary supplement that is indicated in its functional claims to support healthy blood sugar and has shown in clinical studies to reduce after meal sugar spikes.

HNN maintains a database through its affiliate of approximately two million members, many of whom fit the SugarDown market demographic. SugarDown will be test-marketed via trained outbound call center outreach and electronic media.

Fulfillment of all customer orders for SugarDown® will be managed by HNN and other direct distribution channels.

Kenneth A. Tassey, Jr., President, Boston Therapeutics, said, "In our marketing agreement for SugarDown in the United States, we are working with a company that has a broad knowledge of the needs of those who fit our ideal customer profile. HNN has created an impressive database of loyal members. We are confident that HNN will effectively communicate the benefits of SugarDown to these individuals and efficiently distribute the product when orders are placed."

Thomas Scipione of Help Now Networks, added, "We are very excited to introduce SugarDown to our two million members. Over the past several years we have marketed many products that are beneficial to our members to help them better manage their disease. We plan to rollout a marketing campaign for SugarDown in the next few weeks. Help Now Networks is in the business of lead generation through digital media and telemarketing services. For the past five years HNN’s primary focus has been in healthcare of which diabetes has been our core campaign."